pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease
Otsuka Beijing Research
Otsuka Beijing Research Institute
Otsuka Beijing Research is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis, Phenylketonuri
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 33
- Drugs
- 25
- Patents
- 0
20-AVP-786-306
Phase 3 · small molecule · Agitation in Patients With Dementia of the Alzheimer's Type
20-AVP-786-306 for Agitation in Patients With Dementia of the Alzheimer's Type is a Phase 3 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).
Internal code 20-AVP-786-306
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Otsuka Beijing Research Institute
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Agitation in Patients With Dementia of the Alzheimer's Type
- Status
- active
- Trials
- 1